摘要
背景:过去的二十年中,数据支持了阿尔茨海默病的两个假设,即β-淀粉样蛋白假说和“蛋白-蛋白”假说。无疑,Aβ 和 tau 蛋白是目前治疗AD的主要方法。不幸的是,很少有这种治疗方法成功的案例。基于这一点,我们将讨论深部脑刺激作为一种很有前途的治疗策略,旨在恢复大脑活动。最后,在认知缺陷修复的范围,我们将讨论边缘形成的相关性作为脑深部电刺激的有潜力的神经解剖学靶点。 方法:改良tau的免疫组织化学(磷酸化程度 ser199-202–Thr205,AT8抗体标记) 在石蜡包埋人脑切片上进行了研究。对FT病理提供了详细的表征。 结果:异常磷酸化tau蛋白是许多脑疾病如阿尔茨海默病的关键的共同标志,如帕金森病、Pick病、唐氏综合症和额颞叶痴呆及能够影响对记忆的形成至关重要的突触活动。有了这一想法,旨在恢复突触事件的治疗策略,可以提供更好的结果。 结论:目前的治疗方法并不十分理想,以及对脑疾病机制缺乏的基本知识,迫使我们寻求新的替代品以受益于患者。有趣的是,神经刺激的方法已经用于治疗一些运动功能障碍,与目前的阿尔茨海默氏症的治疗相比,深部脑刺激不直接干扰正常的蛋白质功能,因此增加了成功的概率。
关键词: β-淀粉样蛋白,脑疾病,神经刺激,磷酸化,突触失效,突触可塑性,tau蛋白,治疗靶点
Current Alzheimer Research
Title:Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Volume: 14 Issue: 1
Author(s): Siddhartha Mondragón-Rodríguez, George Perry, Fernando Pena-Ortega, Sylvain Williams
Affiliation:
关键词: β-淀粉样蛋白,脑疾病,神经刺激,磷酸化,突触失效,突触可塑性,tau蛋白,治疗靶点
摘要: Background: The last two decades have seen a great advance in the data that supports the two current hypotheses in Alzheimer's disease field, the amyloid beta hypothesis and the tau hypothesis. Not surprisingly, Aβ and tau proteins are currently the major therapeutic research targets for AD treatment. Unfortunately, nothing but moderate success has emerged from such therapeutic approaches. With this in mind, we will discuss deep brain stimulation as a promising therapeutic strategy that aims to restore brain activity. Lastly, in the scope of cognitive deficit restoration, we will discuss the relevance of the limbic formation as a promising neuroanatomical target for deep brain stimulation.
Methods: Immunohistochemistry for modified tau (phosphorylated at Ser199–202–Thr205 labelled by the antibody AT8) was performed on paraffin-embedded human brain sections providing a detailed characterization of NFT pathology. Results: Abnormally phosphorylated tau protein is the key common marker in several brain diseases such as Alzheimer's disease, Parkinson's disease, Pick Disease, Down syndrome and frontotemporal dementia and is capable of affecting synaptic events that are critical for memory formation. With this in mind, therapeutic strategies aiming to restore synaptic events could offer better outcomes. Conclusion: The humble success of current therapeutic strategies along with the lack of basic knowledge of the brain disease mechanisms calls for alternatives that benefit patients in the present moment. One of particular interest is the neurostimulation strategy that is already a well-established treatment for several movement disorders and when compared to current Alzheimer's therapeutic strategies, deep brain stimulation does not directly interfere with the normal protein function, therefore increasing the probability of success.Export Options
About this article
Cite this article as:
Siddhartha Mondragón-Rodríguez, George Perry, Fernando Pena-Ortega, Sylvain Williams , Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease, Current Alzheimer Research 2017; 14 (1) . https://dx.doi.org/10.2174/1567205013666160819131336
DOI https://dx.doi.org/10.2174/1567205013666160819131336 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Obituary
Mini-Reviews in Medicinal Chemistry Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition 1,2,4-Triazole Derivatives as Potential Scaffold for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives
CNS & Neurological Disorders - Drug Targets Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Synaptic Potentiation and Sleep Need: Clues from Molecular and Electrophysiological Studies
Current Topics in Medicinal Chemistry Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology The Medicinal Chemistry of 5-HT6 Receptor Ligands with a Focus on Arylsulfonyltryptamine Analogs
Current Topics in Medicinal Chemistry New Chalcone Derivatives with Pyrazole and Sulfonamide Pharmacophores as Carbonic Anhydrase Inhibitors
Letters in Drug Design & Discovery The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Pediatric Chronic Daily Headache
Current Pediatric Reviews Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Design, Synthesis and Anticonvulsant Activity Evaluation of 7-Substituted –[1,2,4]-Triazolo[4,3-f]Pyrimidine Derivatives
Medicinal Chemistry Histamine H3 Receptor Function and Ligands: Recent Developments
Mini-Reviews in Medicinal Chemistry Editorial: Recent Advances in Pathophysiological Studies and Treatment of Epilepsy
Current Neuropharmacology Lipid Nanocarriers for Neurotherapeutics: Introduction, Challenges, Blood-brain Barrier, and Promises of Delivery Approaches
CNS & Neurological Disorders - Drug Targets Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry